COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.

Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 2

Medicamento de Sinopharm basado en inmunoglobulina humana contra la COVID-19

Perú. Ministerio de Salud. Instituto Nacional de Salud.

ANTECEDENTES: El presente informe se efectúa a solicitud de la jefatura institucional del INS, que solicita opinión sobre el medicamento de Sinopharm basado en inmunoglobulina humana contra la COVID-19. El objetivo del presente informe es brindar la evidencia disponible sobre el medicamento de Sinophar...

COVID-19/drug therapy, Immunoglobulins/therapeutic use, Cost-Benefit Analysis, Efficacy

Fulltext

Plasma convaleciente para el tratamiento de pacientes con COVID-19

Perú. Ministerio de Saud. Instituto Nacional de Salud.

ANTECEDENTES: Los coronavirus son una familia de virus causantes de enfermedades respiratorias, digestivas y del sistema nervioso en humanos y animales. A fines de 2019, se identificó en la provincia de Wuhan, China una cepa de coronavirus nunca antes encontrada en humanos, la cual recibió el nombre de...

Coronavirus Infections/drug therapy, Pneumonia, Viral/drug therapy, Immunoglobulins/therapeutic use, Technology Assessment, Biomedical, Health Evaluation, Betacoronavirus/drug effects

Fulltext